Zentalis Pharmaceuticals (ZNTL)

• Market cap: $263M
• 1 day: 2.21%
• 5 days: 3.93%
• 1 month: 1.93%
• 3 months: 46.83%
• 6 months: 160.56%
• Year to date: 170.07%
• 1 year: 168.12%
• 5 years: -92.62%
• 10 years: -84.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 106